252 related articles for article (PubMed ID: 23123670)
41. Prospective multicenter observational study of encapsulating peritoneal sclerosis with neutral dialysis solution--the NEXT-PD study.
Kawanishi H; Nakayama M; Miyazaki M; Honda K; Tomo T; Kasai K; Nakamoto H;
Adv Perit Dial; 2010; 26():71-4. PubMed ID: 21348384
[TBL] [Abstract][Full Text] [Related]
42. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation.
Ha H; Yu MR; Choi HN; Cha MK; Kang HS; Kim MH; Lee HB
Perit Dial Int; 2000; 20 Suppl 5():S10-8. PubMed ID: 11229606
[TBL] [Abstract][Full Text] [Related]
43. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.
Mortier S; Faict D; Schalkwijk CG; Lameire NH; De Vriese AS
Kidney Int; 2004 Sep; 66(3):1257-65. PubMed ID: 15327425
[TBL] [Abstract][Full Text] [Related]
44. A new neutral-pH low-GDP peritoneal dialysis fluid.
Himmele R; Jensen L; Fenn D; Ho CH; Sawin DA; Diaz-Buxo JA
Perit Dial Int; 2012; 32(4):444-52. PubMed ID: 22383632
[TBL] [Abstract][Full Text] [Related]
45. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
46. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.
Skoufos L; Topley N; Cooker L; Dawnay A; Millar DJ; Holmes CJ; Faict D
Kidney Int Suppl; 2003 Dec; (88):S94-9. PubMed ID: 14870882
[TBL] [Abstract][Full Text] [Related]
47. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis.
Mateijsen MA; van der Wal AC; Hendriks PM; Zweers MM; Mulder J; Struijk DG; Krediet RT
Perit Dial Int; 1999; 19(6):517-25. PubMed ID: 10641771
[TBL] [Abstract][Full Text] [Related]
48. Comparison between standard single chamber versus dual chamber low glucose degradation product peritoneal dialysis fluids.
Vareesangthip K; Vongsanim S; Fan S; Davenport A
Artif Organs; 2021 Jan; 45(1):88-94. PubMed ID: 32645750
[TBL] [Abstract][Full Text] [Related]
49. Unfavorable Effects of Peritoneal Dialysis Solutions on the Peritoneal Membrane: The Role of Oxidative Stress.
Roumeliotis S; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
Biomolecules; 2020 May; 10(5):. PubMed ID: 32423139
[TBL] [Abstract][Full Text] [Related]
50. Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients.
Tawada M; Hamada C; Suzuki Y; Sakata F; Sun T; Kinashi H; Katsuno T; Takei Y; Maruyama S; Honda K; Mizuno M; Ito Y
Clin Exp Nephrol; 2019 May; 23(5):689-699. PubMed ID: 30547267
[TBL] [Abstract][Full Text] [Related]
51. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
52. A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with l-Carnitine Improves Biocompatibility on Human Mesothelial Cells.
Piccapane F; Bonomini M; Castellano G; Gerbino A; Carmosino M; Svelto M; Arduini A; Procino G
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374405
[TBL] [Abstract][Full Text] [Related]
53. Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system.
Passlick-Deetjen J; Lage C
Perit Dial Int; 2000; 20 Suppl 2():S42-7. PubMed ID: 10911642
[No Abstract] [Full Text] [Related]
54. The John F. Maher Recipient Lecture 2004: Rage in the peritoneum.
De Vriese AS
Perit Dial Int; 2005; 25(1):8-11. PubMed ID: 15770917
[TBL] [Abstract][Full Text] [Related]
55. Biological significance of reducing glucose degradation products in peritoneal dialysis fluids.
Wieslander A; Linden T; Musi B; Carlsson O; Deppisch R
Perit Dial Int; 2000; 20 Suppl 5():S23-7. PubMed ID: 11229608
[TBL] [Abstract][Full Text] [Related]
56. Peritoneal dialysis solutions low in glucose degradation products--evidence for clinical benefits.
Tomo T
Perit Dial Int; 2008 Jun; 28 Suppl 3():S123-7. PubMed ID: 18552241
[TBL] [Abstract][Full Text] [Related]
57. Glucose degradation products and the peritoneal mesothelium.
Jörres A; Bender TO; Witowski J
Perit Dial Int; 2000; 20 Suppl 5():S19-22. PubMed ID: 11229607
[TBL] [Abstract][Full Text] [Related]
58. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
[TBL] [Abstract][Full Text] [Related]
59. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
[TBL] [Abstract][Full Text] [Related]
60. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
